Abstract T MP105: Relationship Between Compliance With the Lifestyle Modification Program and Risk Factor Control in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial
Background and Purpose: SAMMPRIS was the first vascular disease prevention trial to provide a commercially available lifestyle modification program to subjects to enhance risk factor control. We sought to determine the relationship between compliance with the lifestyle modification program and risk factor control in SAMMPRIS.
Methods: SAMMPRIS aggressive medical management included a telephonic lifestyle modification program provided free of charge to all subjects (n=451) during their participation in the study. Subjects with < 3 expected lifestyle coaching calls were excluded from these analyses. Subjects with ≥ 78.5% of calls (median % of completed/expected calls) were considered Compliant (n=201). Subjects with < 78.5% and those who refused to participate were considered Noncompliant (n=200). Mean risk factor values or % in-target for each risk factor were compared between Compliant vs. Noncompliant subjects, using t-tests and chi-square tests. Risk factor changes from baseline to follow-up were compared between the groups to account for baseline differences between the groups.
Results: As shown in the figure, Compliant subjects had better risk factor control throughout follow-up for LDL, SBP, HgA1c, non-HDL, non-smoking, and exercise than Noncompliant subjects, but there was no difference for BMI. Compliant subjects also had better control of LDL, non-HDL, and HgA1c at baseline. Both groups had some improvement in risk factors throughout the study (except for BMI), but after adjusting for baseline differences between the groups, Compliant subjects had a greater change from baseline than Noncompliant subjects for SBP at 24 months and HgA1c at 6 months.
Conclusions: SAMMPRIS subjects who were compliant with the lifestyle modification program had better risk factor control during the study for almost all risk factors.
Author Disclosures: T.N. Turan: Employment; Significant; salary support NINDS. A. Nizam: Employment; Significant; salary support NINDS. M.J. Lynn: Employment; Significant; salary support NINDS. J. Montgomery: Employment; Significant; salary support NINDS. C.P. Derdeyn: Employment; Significant; salary support NINDS. D. Fiorella: Employment; Significant; salary support NINDS. B.F. Lane: Employment; Significant; salary support NINDS. S. Janis: None. M.I. Chimowitz: Employment; Significant; salary support NINDS. Research Grant; Significant; U01 NS058728, Neurology PI SAMMPRIS. Other Research Support; Significant; SAMMPRIS corporate support: Stryker Neurovsacular, AstraZeneca.
- © 2014 by American Heart Association, Inc.